[Efficacy and tolerance of cyclosporin A in the treatment of multiple sclerosis].
The use and tolerance of cyclosporine A (Cy A) and azathioprine (AZA) are compared as long-term immunosuppression treatment for multiple sclerosis. 38 patients with multiple sclerosis were randomized and received either Cy A (5 mg/kg/d) or AZA (2 mg/kg/d) during 24 months. These patients were assessed clinically and with different biological parameters. The Cy A blood level was controlled, and Cy A was well tolerated without side effects forcing to stop the treatment. However, its benefits were limited when the different clinical scores are compared.
Schluep
M
M
Service de neurologie, CHUV, Lausanne.
Steck
A J
AJ
Despland
P A
PA
Regli
F
F
Ochsner
F
F
Berrut
E
E
Gauthier
G
G
D000328:Adult; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use*; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*
D003524:Cyclosporins; D001379:Azathioprine
Efficacité et tolérance de la cyclosporine A dans le traitement de la sclérose en plaques.